{"id":538621,"date":"2021-04-14T19:32:01","date_gmt":"2021-04-14T19:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=538621"},"modified":"2021-04-14T19:32:01","modified_gmt":"2021-04-14T19:32:01","slug":"cart-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-abbvie-inc-amgen-inc-atara-biotherapeutics-inc-autolus-therapeutics-plc-bluebird-bio-celgene-gilead","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cart-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-abbvie-inc-amgen-inc-atara-biotherapeutics-inc-autolus-therapeutics-plc-bluebird-bio-celgene-gilead_538621.html","title":{"rendered":"CAR-T Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | AbbVie Inc., Amgen, Inc., Atara Biotherapeutics, Inc., Autolus Therapeutics PLC., bluebird bio, Celgene, Gilead"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"CAR-T Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | AbbVie Inc., Amgen, Inc., Atara Biotherapeutics, Inc., Autolus Therapeutics PLC., bluebird bio, Celgene, Gilead\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"CAR-T Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | AbbVie Inc., Amgen, Inc., Atara Biotherapeutics, Inc., Autolus Therapeutics PLC., bluebird bio, Celgene, Gilead\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>CAR-T Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>CAR-T<\/strong> is a type of treatment in which a patient&#8217;s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient&rsquo;s blood. Then the gene for a special receptor that binds to a certain protein on the patient&rsquo;s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. <strong>CAR T-cell therapy<\/strong> is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;<strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">CAR-T Pipeline<\/a> Insights, 2021,&rdquo;<\/strong>&nbsp;report provides comprehensive insights about <strong>250+ companies and 250+ pipeline drugs<\/strong> in CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get free sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/car-t-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/car-t-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the CAR-T Companies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>AbbVie Inc.<\/li>\n<li>Adaptimmune Therapeutics PLC.<\/li>\n<li>Amgen, Inc.<\/li>\n<li>Atara Biotherapeutics, Inc.<\/li>\n<li>Aurora Biopharma, Inc.<\/li>\n<li>Autolus Therapeutics PLC.<\/li>\n<li>Bellicum Pharmaceuticals, Inc.<\/li>\n<li>BioAtla LLC.<\/li>\n<li>bluebird bio<\/li>\n<li>Carina Biotech<\/li>\n<li>CARsgen Therapeutics, Ltd.<\/li>\n<li>CARTherics<\/li>\n<li>Celgene<\/li>\n<li>Cellectis<\/li>\n<li>Celularity<\/li>\n<li>Celyad SA<\/li>\n<li>Creative Biolabs<\/li>\n<li>DiaCarta, Inc.<\/li>\n<li>Endocyte, Inc.<\/li>\n<li>F1 Oncology, Inc.<\/li>\n<li>Fate Therapeutics Inc.<\/li>\n<li>Gilead<\/li>\n<li>Humanigen, Inc.<\/li>\n<li>Immune Therapeutics, Inc.<\/li>\n<li>Intrexon, Corp.<\/li>\n<li>Juno Therapeutics, Inc.<\/li>\n<li>Kite Pharma, Inc.<\/li>\n<li>Lion TCR Pte Ltd.<\/li>\n<li>MaxCyte, Inc.<\/li>\n<li>Mesoblast, Ltd.<\/li>\n<li>Minerva Biotechnologies Corp.<\/li>\n<li>Mustang Bio, Inc.<\/li>\n<li>Novartis AG<\/li>\n<li>Oxford BioMedica PLC.<\/li>\n<li>PeproMene Bio Inc.<\/li>\n<li>Pfizer, Inc.<\/li>\n<li>Posedia Therapeutics Inc.<\/li>\n<li>Precision Biosciences, Inc.<\/li>\n<li>ProMab Biotechnologies Inc.<\/li>\n<li>Servier Oncology<\/li>\n<li>Sorrento Therapeutics, Inc.<\/li>\n<li>TC Biopharm Ltd.<\/li>\n<li>Tessa Therapeutics Pte Ltd.<\/li>\n<li>TILT Biotherapeutics Ltd.<\/li>\n<li>Tmunity Therapeutics Inc.<\/li>\n<li>TrakCel Ltd.<\/li>\n<li>Xyphos<\/li>\n<li>ZIOPHARM Oncology, Inc.<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get free sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/car-t-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/car-t-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">CAR-T Therapies<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>LCAR-B38M CAR-T Cell<\/li>\n<li>&nbsp;Anti-CEA CAR-T cells<\/li>\n<li>&nbsp;CD30.CAR-T<\/li>\n<li>&nbsp;AUTO CAR T cell therapy<\/li>\n<li>&nbsp;Defibrotide<\/li>\n<li>&nbsp;MB-CART2019.1 Dose level 1<\/li>\n<li>&nbsp;CAR-T<\/li>\n<li>&nbsp;CD19\/22 CART<\/li>\n<li>&nbsp;JNJ-68284528<\/li>\n<li>&nbsp;CD123 CAR-T cells<\/li>\n<li>&nbsp;CD19 CAR-T cells<\/li>\n<li>&nbsp;BCMA CAR-T cells<\/li>\n<li>&nbsp;CEA CAR-T cells<\/li>\n<li>&nbsp;CAR-T cell immunotherapy<\/li>\n<li>&nbsp;Autologous CAR-T cells<\/li>\n<li>&nbsp;Second generation CAR-T cells<\/li>\n<li>&nbsp;CAR-T\/TCR-T cells immunotherapy<\/li>\n<li>&nbsp;Allogeneic hematological stem cell transplantation<\/li>\n<li>&nbsp;Humanized CD19 CAR-T cells<\/li>\n<li>&nbsp;CD19 CART<\/li>\n<li>&nbsp;MB-CART20.1<\/li>\n<li>&nbsp;MB-CART19.1<\/li>\n<li>&nbsp;IM19 CAR-T Cells<\/li>\n<li>&nbsp;CLDN6 CAR-T<\/li>\n<li>&nbsp;Autologous CD19-targeting CAR T cells<\/li>\n<li>&nbsp;P-BCMA-101 CAR-T cells<\/li>\n<li>&nbsp;MLM-CAR44.1 T-cells, cyclophosphamide and fludarabine from -5 to -3<\/li>\n<li>&nbsp;CART-19\/22<\/li>\n<li>&nbsp;Anakinra<\/li>\n<li>&nbsp;Anti-MUC1 CAR-T cells<\/li>\n<li>&nbsp;CAR T-cell therapy<\/li>\n<li>&nbsp;CAR T cells<\/li>\n<li>&nbsp;CART-19<\/li>\n<li>&nbsp;CAR-CD19 T Cells<\/li>\n<li>&nbsp;CAR-BCMA T Cells<\/li>\n<li>&nbsp;LCAR-B38M CAR-T cell injection<\/li>\n<li>&nbsp;AUTO1<\/li>\n<li>&nbsp;AUTO3<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get free sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/car-t-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/car-t-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">CAR-T: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">CAR-T &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">&bull; CAR-T companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">CAR-T Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">JNJ-68284528: Janssen Research &amp; Development, LLC<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">LCAR-B38M CAR-T Cell: Nanjing Legend Biotech Co.<\/p>\n<p style=\"text-align: justify;\">CD30.CAR-T: Tessa Therapeutics<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">IM21 CAR-T cells: Beijing Immunochina Medical Science &amp; Technology Co., Ltd.<\/p>\n<p style=\"text-align: justify;\">Pre-clinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Research programme: CAR-T cell therapy &#8211; Endocyte\/Seattle Childrens Research Institute<\/p>\n<p style=\"text-align: justify;\">Research programme: chimeric antigen receptor T cell therapies &#8211; CRISPR Therapeutics<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">CAR-T- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cart-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-abbvie-inc-amgen-inc-atara-biotherapeutics-inc-autolus-therapeutics-plc-bluebird-bio-celgene-gilead\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/car-t-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/car-t-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cart-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-abbvie-inc-amgen-inc-atara-biotherapeutics-inc-autolus-therapeutics-plc-bluebird-bio-celgene-gilead\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAR-T Pipeline CAR-T is a type of treatment in which a patient&#8217;s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient&rsquo;s blood. Then &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cart-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-abbvie-inc-amgen-inc-atara-biotherapeutics-inc-autolus-therapeutics-plc-bluebird-bio-celgene-gilead_538621.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-538621","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=538621"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538621\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=538621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=538621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=538621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}